Literature DB >> 11994568

Hereditary hemorrhagic telangiectasia, factor V Leiden and antiphospholipid syndrome: a case report.

A Undas1, S Bazan-Socha, J Swadzba, J Musial.   

Abstract

We report on a 57-year-old woman with three episodes of ischemic strokes and hereditary hemorrhagic telangiectasia (HHT). Tests for inherited and acquired thrombophilia showed elevated anticardiolipin immunoglobulin (Ig)M antibodies (on three separate occasions), anti-prothrombin IgG antibodies, and the heterozygous form of factor V Leiden. This is the first case of HHT, a primary antiphospholipid syndrome, combined with factor V Leiden. No detectable arteriovenous malformation was found and ischemic episodes, documented by computer tomography, were related to the presence of antiphospholipid antibodies and possibly the carriership of factor V Leiden mutation. Since aspirin provoked severe nasal hemorrhages, treatment with ticlopidine was initiated after the third stroke. Over an 18-month follow-up, ischemic episodes were absent and we regarded oral anticoagulation as unjustifiable.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11994568     DOI: 10.1097/00001721-200201000-00008

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  3 in total

1.  Hereditary haemorrhagic telangiectasia and genetic thrombophilia.

Authors:  S Bianca; N Cutuli; M Bianca; B Barrano; A Cataliotti; C Barone; L Indaco; G Milana
Journal:  Eur J Hum Genet       Date:  2009-11-11       Impact factor: 4.246

2.  Cerebrovascular Events Secondary to Pulmonary Arteriovenous Malformation Based on Genetic Heterogeneity.

Authors:  Güner Çelik; Hüseyin Yurdakul; Erkan Yildirim
Journal:  Noro Psikiyatr Ars       Date:  2016-09-20       Impact factor: 1.339

3.  Interventional embolization of a giant pulmonary arteriovenous malformation with right-left-shunt associated with hereditary hemorrhagic telangiectasia.

Authors:  M Hinterseer; A Becker; A S Barth; R Kozlik-Feldmann; B J Wintersperger; J Behr
Journal:  Clin Res Cardiol       Date:  2006-01-19       Impact factor: 5.460

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.